How Graham Platner's Campaign Is Trying to Do Damage Control After Nazi Tattoo...
Even CNN Is Calling Out Dems Over This Lie About Trump's White House...
Is This the Most Insane Reaction to President Trump's East Wing Project
LOL: The White House Did Not Include *This* on Their Website. It's Classic...
'Lassie' and 'Lost in Space' Actress June Lockhart Dead at 100
When There Are No Words: Hundreds Honor Teen Who Gave Life After Losing...
What Could Go Wrong? Scientists May Have Found a Real-Life Jurassic Park Starter...
Trump Administration Fires Back at Hillary Clinton Over White House Ballroom Renovations
Two Defendants Convicted of Conspiring to Provide Material Support to ISIS
Justice Department to Monitor Polling Sites in California, New Jersey
Chicago Mayor Brandon Johnson Asks Reporter if the Word Illegal Alien is 'Sci-Fi'...
Zohran Mamdani Says That Muslims Were Hit Hard After 9/11
Feds Charge 33 in Philadelphia’s Most Prolific Drug Market: Weymouth Street DTO
What Charlie Kirk Understood About America’s Lost Youth
Abigail Spanberger, As Governor, You’re Supposed to Make Decisions
Tipsheet
Premium

British Researchers Make Major Discovery That Has Potential to 'Kill Most Cancers from All People'

NCI Center for Cancer Research/NIH via AP

British scientists have stumbled upon a new type of immune cell that appears to kill most cancers, while leaving healthy cells alone.

Researchers at Cardiff University made the exciting discovering of the new T-cell when they were examining blood for an immune cell that could fight bacteria, igniting hopes of a “‘one-size-fits-all’ cancer therapy.”

“So we’ve found a new type of white blood cell that has the capacity to kill most cancers from all people,” says Cardiff University’s School of Medicine Professor Andrew Sewell in a video explaining the discovery. 


Conventional T-cells scan the surface of other cells to find anomalies and eliminate cancerous cells - which express abnormal proteins - but ignore cells that contain only “normal” proteins.

The scanning system recognises small parts of cellular proteins that are bound to cell-surface molecules called human leukocyte antigen (HLA), allowing killer T-cells to see what’s occurring inside cells by scanning their surface.

HLA varies widely between individuals, which has previously prevented scientists from creating a single T-cell-based treatment that targets most cancers in all people.

But the Cardiff study, published today in Nature Immunology, describes a unique TCR that can recognise many types of cancer via a single HLA-like molecule called MR1.

Unlike HLA, MR1 does not vary in the human population - meaning it is a hugely attractive new target for immunotherapies. (Cardiff University)

The discovery offers “'exciting opportunities for pan-cancer, pan-population” immunotherapies not previously thought possible,’” researchers said.

In the lab, the new treatment killed lung, skin, blood, colon, breast, bone, prostate, kidney, cervical, and ovarian cancer cells, while ignoring healthy cells.

“We hope this new TCR may provide us with a different route to target and destroy a wide range of cancers in all individuals,” said Sewell, lead author of the study.

“Current TCR-based therapies can only be used in a minority of patients with a minority of cancers,” he continued. “Cancer-targeting via MR1-restricted T-cells is an exciting new frontier - it raises the prospect of a ‘one-size-fits-all’ cancer treatment; a single type of T-cell that could be capable of destroying many different types of cancers across the population."

While much testing still remains to be done, the breakthrough is encouraging. 

“Previously nobody believed this could be possible,” Sewell said.

Recommended

Trending on Townhall Videos